Clinical Trials Logo

Clinical Trial Summary

A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase II Clinical Trial to Evaluate the Efficacy and Safety of HU-045 and Xeomin® in Patients With Moderate to Severe Glabellar Lines


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06205797
Study type Interventional
Source Huons Biopharma
Contact SUNGGUK CHO
Phone +82-02-854-4700
Email sgcho@huons.com
Status Not yet recruiting
Phase Phase 3
Start date March 15, 2024
Completion date July 31, 2025

See also
  Status Clinical Trial Phase
Completed NCT04096326 - AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines Phase 2
Completed NCT02961673 - The Safety and Efficacy Study of HU-014 Versus Botox® in Subject With Moderate to Severe Glabellar Lines Phase 1/Phase 2
Completed NCT01271452 - Safety and Efficacy of Two Types of Botulinum Toxin Type A For the Treatment of Glabellar Lines Phase 4
Completed NCT05013424 - A Study of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines Phase 2
Completed NCT01189760 - Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines Phase 3
Completed NCT05100199 - A Study to the Assess the Change in Condition and Adverse Events of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines Phase 2
Completed NCT03721016 - MT10109L in the Treatment of Glabellar Lines (GL) With or Without Concurrent Treatment of Lateral Canthal Lines (LCL) Phase 3
Completed NCT04157686 - MT10109L in the Long-term, Open-label Treatment of Glabellar Lines (GL) and Lateral Canthal Lines (LCL) Phase 3
Completed NCT02353897 - Patient and Physician's Satisfaction After a Long Term Treatment of Glabellar Lines With Dysport®
Completed NCT03732833 - MT10109L in the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines Phase 3
Completed NCT06212960 - Evaluate the Safety and Explore the Efficacy of DWP712 With Moderate to Severe Glabellar Lines Phase 1
Completed NCT05089357 - Non-interventional Study, Long Term Treatment on Glabellar Lines With Dysport® in Subjects of Chinese Origin
Completed NCT00408785 - A Study Of BOTOX For The Treatment Of Glabellar Lines Phase 3
Completed NCT05380154 - Efficacy and Safety Assessment of Botulax® and BOTOX® for Improvement of Glabellar Lines. Phase 3
Completed NCT01224015 - Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines Phase 3
Completed NCT05248880 - A Study to Assess Adverse Events and Change in Disease Activity of Intramuscular AGN-151586 Injection in Toxin-Naïve Adult Participants With Glabellar Lines Phase 3
Completed NCT03216408 - Clinical Study to Evaluate the Efficacy and Safety of Neuronox and Botox With Moderate to Severe Glabellar Lines Phase 3
Recruiting NCT06308198 - A Study to Evaluate AGN-151586 Intramuscular Injections in Adult Participants for Treatment of Glabellar Lines Phase 3
Completed NCT05298449 - Phase 2 of HU-045 in Glabellar Lines Phase 2
Not yet recruiting NCT06246552 - Clinical Trial to Evaluate the Safety and Efficacy of JTM201 to Treat Moderate or Severe Glabellar Lines Phase 2